|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||95.00 - 95.00|
|52 Week Range||90.00 - 150.00|
|Beta (3Y Monthly)||1.70|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 7, 2019 - Feb 11, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||150.00|
Oncimmune Holdings plc (ONC.L), a leading early cancer detection company developing and commercializing its proprietary EarlyCDT® liquid biopsy platform technology, today presented new data demonstrating the clinical utility of EarlyCDT-Lung, a simple blood test for the early detection of lung cancer, in determining malignancy risk in indeterminate pulmonary nodules (IPNs). In a presentation today at the IASLC 19th World Conference on Lung Cancer in Toronto, Canada, hosted by the International Association for the Study of Lung Cancer (#WCLC2018), Oncimmune researchers reported that for IPNs of 6-20mm with a lung cancer probability of 30%, combining a positive EarlyCDT-Lung result with a standard risk calculator produced a positive predictive value (PPV) of 91%, versus a 48% PPV using the standard risk calculator alone.
Nottingham, UK – 13 September 2018: Oncimmune Holdings plc (ONC.L), a leading early cancer detection company developing and commercialising its proprietary EarlyCDT® liquid biopsy platform technology, today announces the appointment of Marco Casarin as General Manager, Oncimmune USA LLC. Marco has more than 25 years of global healthcare experience particularly within large and multinational lab and diagnostic services companies. Marco was most recently at Thermo Fisher Scientific Inc and previously his roles have included senior commercial, marketing and operational roles at Roche Diagnostics and Vela Diagnostics, which he also co-founded.
Companies that have significant growth prospects for profitability and returns can add tangible upside to your portfolio. Oncimmune Holdings and APQ Global are examples of many potential outperformers that analystsRead More...